nodes	percent_of_prediction	percent_of_DWPC	metapath
Medroxyprogesterone Acetate—HSD3B2—digestive system—esophageal cancer	0.011	0.0971	CbGeAlD
Medroxyprogesterone Acetate—SHBG—neck—esophageal cancer	0.00673	0.0595	CbGeAlD
Medroxyprogesterone Acetate—HSD3B2—lymph node—esophageal cancer	0.00628	0.0555	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—bronchus—esophageal cancer	0.006	0.053	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—smooth muscle tissue—esophageal cancer	0.00587	0.0519	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—trachea—esophageal cancer	0.00539	0.0476	CbGeAlD
Medroxyprogesterone Acetate—ESR1—neck—esophageal cancer	0.00474	0.0419	CbGeAlD
Medroxyprogesterone Acetate—Cyproterone acetate—CYP19A1—esophageal cancer	0.00423	0.261	CrCbGaD
Medroxyprogesterone Acetate—PGR—epithelium—esophageal cancer	0.00413	0.0365	CbGeAlD
Medroxyprogesterone Acetate—PGR—smooth muscle tissue—esophageal cancer	0.00398	0.0351	CbGeAlD
Medroxyprogesterone Acetate—AKR1C3—lung—esophageal cancer	0.00387	0.0342	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—neck—esophageal cancer	0.0035	0.0309	CbGeAlD
Medroxyprogesterone Acetate—AR—epithelium—esophageal cancer	0.00329	0.0291	CbGeAlD
Medroxyprogesterone Acetate—AR—bronchus—esophageal cancer	0.00324	0.0286	CbGeAlD
Medroxyprogesterone Acetate—ESR1—epithelium—esophageal cancer	0.00323	0.0285	CbGeAlD
Medroxyprogesterone Acetate—AR—smooth muscle tissue—esophageal cancer	0.00317	0.028	CbGeAlD
Medroxyprogesterone Acetate—ESR1—smooth muscle tissue—esophageal cancer	0.00311	0.0275	CbGeAlD
Medroxyprogesterone Acetate—Hydrocortisone—ANXA1—esophageal cancer	0.00286	0.176	CrCbGaD
Medroxyprogesterone Acetate—AKR1C3—lymph node—esophageal cancer	0.00265	0.0234	CbGeAlD
Medroxyprogesterone Acetate—PGR—lung—esophageal cancer	0.00262	0.0232	CbGeAlD
Medroxyprogesterone Acetate—AR—digestive system—esophageal cancer	0.0025	0.0221	CbGeAlD
Medroxyprogesterone Acetate—ESR1—digestive system—esophageal cancer	0.00246	0.0217	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—epithelium—esophageal cancer	0.00238	0.021	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—bronchus—esophageal cancer	0.00235	0.0207	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—smooth muscle tissue—esophageal cancer	0.00229	0.0203	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—trachea—esophageal cancer	0.00211	0.0186	CbGeAlD
Medroxyprogesterone Acetate—AR—lung—esophageal cancer	0.00209	0.0185	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lung—esophageal cancer	0.00205	0.0181	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—digestive system—esophageal cancer	0.00181	0.016	CbGeAlD
Medroxyprogesterone Acetate—CYP2C9—digestive system—esophageal cancer	0.0018	0.0159	CbGeAlD
Medroxyprogesterone Acetate—PGR—lymph node—esophageal cancer	0.00179	0.0158	CbGeAlD
Medroxyprogesterone Acetate—NR3C1—lung—esophageal cancer	0.00151	0.0134	CbGeAlD
Medroxyprogesterone Acetate—AR—lymph node—esophageal cancer	0.00143	0.0126	CbGeAlD
Medroxyprogesterone Acetate—ESR1—lymph node—esophageal cancer	0.0014	0.0124	CbGeAlD
Medroxyprogesterone Acetate—CYP3A4—digestive system—esophageal cancer	0.00137	0.0121	CbGeAlD
Medroxyprogesterone Acetate—Spironolactone—ABCC2—esophageal cancer	0.00134	0.0823	CrCbGaD
Medroxyprogesterone Acetate—Methyltestosterone—CYP19A1—esophageal cancer	0.00111	0.0683	CrCbGaD
Medroxyprogesterone Acetate—NR3C1—lymph node—esophageal cancer	0.00103	0.00914	CbGeAlD
Medroxyprogesterone Acetate—Irritability—Capecitabine—esophageal cancer	0.001	0.0021	CcSEcCtD
Medroxyprogesterone Acetate—Urinary retention—Capecitabine—esophageal cancer	0.000997	0.00209	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Capecitabine—esophageal cancer	0.000993	0.00208	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Capecitabine—esophageal cancer	0.000986	0.00206	CcSEcCtD
Medroxyprogesterone Acetate—Blood creatinine increased—Capecitabine—esophageal cancer	0.000982	0.00206	CcSEcCtD
Medroxyprogesterone Acetate—Bladder pain—Methotrexate—esophageal cancer	0.000972	0.00204	CcSEcCtD
Medroxyprogesterone Acetate—Neoplasm—Methotrexate—esophageal cancer	0.000972	0.00204	CcSEcCtD
Medroxyprogesterone Acetate—Mouth ulceration—Methotrexate—esophageal cancer	0.000972	0.00204	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Cisplatin—esophageal cancer	0.000972	0.00203	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Cisplatin—esophageal cancer	0.000967	0.00202	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Cisplatin—esophageal cancer	0.000965	0.00202	CcSEcCtD
Medroxyprogesterone Acetate—Dry skin—Capecitabine—esophageal cancer	0.000961	0.00201	CcSEcCtD
Medroxyprogesterone Acetate—Orthostatic hypotension—Capecitabine—esophageal cancer	0.000958	0.00201	CcSEcCtD
Medroxyprogesterone Acetate—Hypokalaemia—Capecitabine—esophageal cancer	0.000954	0.002	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Cisplatin—esophageal cancer	0.000948	0.00199	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Capecitabine—esophageal cancer	0.000947	0.00198	CcSEcCtD
Medroxyprogesterone Acetate—Nasopharyngitis—Capecitabine—esophageal cancer	0.000938	0.00196	CcSEcCtD
Medroxyprogesterone Acetate—Sepsis—Methotrexate—esophageal cancer	0.000933	0.00195	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—CYP1B1—esophageal cancer	0.000928	0.0571	CrCbGaD
Medroxyprogesterone Acetate—Alanine aminotransferase increased—Capecitabine—esophageal cancer	0.000925	0.00194	CcSEcCtD
Medroxyprogesterone Acetate—Muscular weakness—Capecitabine—esophageal cancer	0.000925	0.00194	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Cisplatin—esophageal cancer	0.00092	0.00193	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Cisplatin—esophageal cancer	0.000917	0.00192	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Cisplatin—esophageal cancer	0.000913	0.00191	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal distension—Capecitabine—esophageal cancer	0.000912	0.00191	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Capecitabine—esophageal cancer	0.000906	0.0019	CcSEcCtD
Medroxyprogesterone Acetate—Influenza—Capecitabine—esophageal cancer	0.000906	0.0019	CcSEcCtD
Medroxyprogesterone Acetate—Dysphagia—Capecitabine—esophageal cancer	0.000906	0.0019	CcSEcCtD
Medroxyprogesterone Acetate—Thrombophlebitis—Methotrexate—esophageal cancer	0.000902	0.00189	CcSEcCtD
Medroxyprogesterone Acetate—Diabetes mellitus—Methotrexate—esophageal cancer	0.000897	0.00188	CcSEcCtD
Medroxyprogesterone Acetate—Bronchospasm—Capecitabine—esophageal cancer	0.000891	0.00187	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Cisplatin—esophageal cancer	0.000889	0.00186	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Cisplatin—esophageal cancer	0.000887	0.00186	CcSEcCtD
Medroxyprogesterone Acetate—Sweating increased—Capecitabine—esophageal cancer	0.000883	0.00185	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—CYP1B1—esophageal cancer	0.000877	0.054	CrCbGaD
Medroxyprogesterone Acetate—Bronchitis—Capecitabine—esophageal cancer	0.000871	0.00182	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Cisplatin—esophageal cancer	0.000869	0.00182	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Capecitabine—esophageal cancer	0.000869	0.00182	CcSEcCtD
Medroxyprogesterone Acetate—Hepatic failure—Methotrexate—esophageal cancer	0.000868	0.00182	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Cisplatin—esophageal cancer	0.000857	0.00179	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Cisplatin—esophageal cancer	0.000857	0.00179	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Capecitabine—esophageal cancer	0.000847	0.00177	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Cisplatin—esophageal cancer	0.000844	0.00177	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Capecitabine—esophageal cancer	0.000842	0.00176	CcSEcCtD
Medroxyprogesterone Acetate—Weight increased—Capecitabine—esophageal cancer	0.000825	0.00173	CcSEcCtD
Medroxyprogesterone Acetate—Visual disturbance—Methotrexate—esophageal cancer	0.000824	0.00172	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Cisplatin—esophageal cancer	0.000823	0.00172	CcSEcCtD
Medroxyprogesterone Acetate—Weight decreased—Capecitabine—esophageal cancer	0.00082	0.00172	CcSEcCtD
Medroxyprogesterone Acetate—Hyperglycaemia—Capecitabine—esophageal cancer	0.000817	0.00171	CcSEcCtD
Medroxyprogesterone Acetate—Drospirenone—PTGS2—esophageal cancer	0.000812	0.05	CrCbGaD
Medroxyprogesterone Acetate—Infestation—Capecitabine—esophageal cancer	0.000808	0.00169	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Capecitabine—esophageal cancer	0.000808	0.00169	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactoid reaction—Methotrexate—esophageal cancer	0.000806	0.00169	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Capecitabine—esophageal cancer	0.000806	0.00169	CcSEcCtD
Medroxyprogesterone Acetate—Tremor—Cisplatin—esophageal cancer	0.000802	0.00168	CcSEcCtD
Medroxyprogesterone Acetate—Acute coronary syndrome—Capecitabine—esophageal cancer	0.000796	0.00167	CcSEcCtD
Medroxyprogesterone Acetate—Cerebrovascular accident—Methotrexate—esophageal cancer	0.000796	0.00167	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Cisplatin—esophageal cancer	0.000795	0.00166	CcSEcCtD
Medroxyprogesterone Acetate—Myocardial infarction—Capecitabine—esophageal cancer	0.000792	0.00166	CcSEcCtD
Medroxyprogesterone Acetate—Neuropathy peripheral—Capecitabine—esophageal cancer	0.000792	0.00166	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Cisplatin—esophageal cancer	0.000792	0.00166	CcSEcCtD
Medroxyprogesterone Acetate—Megestrol acetate—ABCB1—esophageal cancer	0.000791	0.0487	CrCbGaD
Medroxyprogesterone Acetate—Jaundice—Capecitabine—esophageal cancer	0.000788	0.00165	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Capecitabine—esophageal cancer	0.000788	0.00165	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract infection—Capecitabine—esophageal cancer	0.000785	0.00164	CcSEcCtD
Medroxyprogesterone Acetate—Osteoarthritis—Methotrexate—esophageal cancer	0.00078	0.00163	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Cisplatin—esophageal cancer	0.000772	0.00162	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Capecitabine—esophageal cancer	0.000764	0.0016	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Capecitabine—esophageal cancer	0.000762	0.0016	CcSEcCtD
Medroxyprogesterone Acetate—Irritability—Methotrexate—esophageal cancer	0.000745	0.00156	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Cisplatin—esophageal cancer	0.000742	0.00155	CcSEcCtD
Medroxyprogesterone Acetate—Mood swings—Methotrexate—esophageal cancer	0.000739	0.00155	CcSEcCtD
Medroxyprogesterone Acetate—Bradycardia—Capecitabine—esophageal cancer	0.000738	0.00155	CcSEcCtD
Medroxyprogesterone Acetate—Ataxia—Methotrexate—esophageal cancer	0.000734	0.00154	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Cisplatin—esophageal cancer	0.000729	0.00153	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Capecitabine—esophageal cancer	0.000729	0.00153	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Cisplatin—esophageal cancer	0.000727	0.00152	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Capecitabine—esophageal cancer	0.000725	0.00152	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Capecitabine—esophageal cancer	0.000725	0.00152	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Cisplatin—esophageal cancer	0.000724	0.00152	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Cisplatin—esophageal cancer	0.00072	0.00151	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Capecitabine—esophageal cancer	0.00072	0.00151	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Capecitabine—esophageal cancer	0.000716	0.0015	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—CYP2A6—esophageal cancer	0.000715	0.044	CrCbGaD
Medroxyprogesterone Acetate—Oedema peripheral—Capecitabine—esophageal cancer	0.000715	0.0015	CcSEcCtD
Medroxyprogesterone Acetate—Connective tissue disorder—Capecitabine—esophageal cancer	0.000713	0.00149	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Capecitabine—esophageal cancer	0.000711	0.00149	CcSEcCtD
Medroxyprogesterone Acetate—Breast disorder—Methotrexate—esophageal cancer	0.000705	0.00148	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Cisplatin—esophageal cancer	0.000699	0.00146	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Cisplatin—esophageal cancer	0.000699	0.00146	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Capecitabine—esophageal cancer	0.000699	0.00146	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Cisplatin—esophageal cancer	0.000694	0.00145	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Capecitabine—esophageal cancer	0.000686	0.00144	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Cisplatin—esophageal cancer	0.000686	0.00144	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Cisplatin—esophageal cancer	0.000684	0.00143	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Cisplatin—esophageal cancer	0.000682	0.00143	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Cisplatin—esophageal cancer	0.000679	0.00142	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Capecitabine—esophageal cancer	0.000678	0.00142	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Capecitabine—esophageal cancer	0.000676	0.00142	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Cisplatin—esophageal cancer	0.000676	0.00142	CcSEcCtD
Medroxyprogesterone Acetate—Asthma—Methotrexate—esophageal cancer	0.000675	0.00141	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Capecitabine—esophageal cancer	0.000673	0.00141	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Cisplatin—esophageal cancer	0.000666	0.0014	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Capecitabine—esophageal cancer	0.000658	0.00138	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Capecitabine—esophageal cancer	0.000655	0.00137	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Capecitabine—esophageal cancer	0.000654	0.00137	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Cisplatin—esophageal cancer	0.000653	0.00137	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Capecitabine—esophageal cancer	0.000651	0.00136	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal discomfort—Methotrexate—esophageal cancer	0.000647	0.00135	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—CYP19A1—esophageal cancer	0.000644	0.0396	CrCbGaD
Medroxyprogesterone Acetate—Alopecia—Capecitabine—esophageal cancer	0.000641	0.00134	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Cisplatin—esophageal cancer	0.000637	0.00133	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Capecitabine—esophageal cancer	0.000635	0.00133	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Capecitabine—esophageal cancer	0.000631	0.00132	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Capecitabine—esophageal cancer	0.000631	0.00132	CcSEcCtD
Medroxyprogesterone Acetate—Dysuria—Methotrexate—esophageal cancer	0.000631	0.00132	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Cisplatin—esophageal cancer	0.000628	0.00131	CcSEcCtD
Medroxyprogesterone Acetate—Upper respiratory tract infection—Methotrexate—esophageal cancer	0.000627	0.00131	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Cisplatin—esophageal cancer	0.000623	0.00131	CcSEcCtD
Medroxyprogesterone Acetate—Flatulence—Capecitabine—esophageal cancer	0.000622	0.0013	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Capecitabine—esophageal cancer	0.000618	0.00129	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Capecitabine—esophageal cancer	0.000611	0.00128	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Cisplatin—esophageal cancer	0.000608	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Muscle spasms—Capecitabine—esophageal cancer	0.000607	0.00127	CcSEcCtD
Medroxyprogesterone Acetate—Methylprednisolone—ABCB1—esophageal cancer	0.000606	0.0373	CrCbGaD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Cisplatin—esophageal cancer	0.000604	0.00126	CcSEcCtD
Medroxyprogesterone Acetate—Infestation NOS—Methotrexate—esophageal cancer	0.000601	0.00126	CcSEcCtD
Medroxyprogesterone Acetate—Infestation—Methotrexate—esophageal cancer	0.000601	0.00126	CcSEcCtD
Medroxyprogesterone Acetate—Drowsiness—Methotrexate—esophageal cancer	0.000601	0.00126	CcSEcCtD
Medroxyprogesterone Acetate—Depression—Methotrexate—esophageal cancer	0.0006	0.00126	CcSEcCtD
Medroxyprogesterone Acetate—Tremor—Capecitabine—esophageal cancer	0.000592	0.00124	CcSEcCtD
Medroxyprogesterone Acetate—Stomatitis—Methotrexate—esophageal cancer	0.000586	0.00123	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Capecitabine—esophageal cancer	0.000586	0.00123	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Capecitabine—esophageal cancer	0.000584	0.00122	CcSEcCtD
Medroxyprogesterone Acetate—Sweating—Methotrexate—esophageal cancer	0.000577	0.00121	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Cisplatin—esophageal cancer	0.000576	0.00121	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Capecitabine—esophageal cancer	0.000569	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Hepatobiliary disease—Methotrexate—esophageal cancer	0.000569	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Epistaxis—Methotrexate—esophageal cancer	0.000567	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Capecitabine—esophageal cancer	0.000567	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Syncope—Capecitabine—esophageal cancer	0.000566	0.00119	CcSEcCtD
Medroxyprogesterone Acetate—Palpitations—Capecitabine—esophageal cancer	0.000558	0.00117	CcSEcCtD
Medroxyprogesterone Acetate—Loss of consciousness—Capecitabine—esophageal cancer	0.000555	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Cisplatin—esophageal cancer	0.000553	0.00116	CcSEcCtD
Medroxyprogesterone Acetate—Haemoglobin—Methotrexate—esophageal cancer	0.000543	0.00114	CcSEcCtD
Medroxyprogesterone Acetate—Haemorrhage—Methotrexate—esophageal cancer	0.00054	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Hepatitis—Methotrexate—esophageal cancer	0.00054	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Capecitabine—esophageal cancer	0.000538	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Capecitabine—esophageal cancer	0.000538	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Capecitabine—esophageal cancer	0.000538	0.00113	CcSEcCtD
Medroxyprogesterone Acetate—Pharyngitis—Methotrexate—esophageal cancer	0.000536	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Anxiety—Capecitabine—esophageal cancer	0.000536	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Capecitabine—esophageal cancer	0.000534	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Urinary tract disorder—Methotrexate—esophageal cancer	0.000533	0.00112	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Capecitabine—esophageal cancer	0.000531	0.00111	CcSEcCtD
Medroxyprogesterone Acetate—Urethral disorder—Methotrexate—esophageal cancer	0.000529	0.00111	CcSEcCtD
Medroxyprogesterone Acetate—Dry mouth—Capecitabine—esophageal cancer	0.000526	0.0011	CcSEcCtD
Medroxyprogesterone Acetate—Visual impairment—Methotrexate—esophageal cancer	0.00052	0.00109	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Capecitabine—esophageal cancer	0.00052	0.00109	CcSEcCtD
Medroxyprogesterone Acetate—Oedema—Capecitabine—esophageal cancer	0.000515	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Cisplatin—esophageal cancer	0.000515	0.00108	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Capecitabine—esophageal cancer	0.000512	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Erythema multiforme—Methotrexate—esophageal cancer	0.000511	0.00107	CcSEcCtD
Medroxyprogesterone Acetate—Shock—Capecitabine—esophageal cancer	0.000507	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Capecitabine—esophageal cancer	0.000505	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Eye disorder—Methotrexate—esophageal cancer	0.000505	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Capecitabine—esophageal cancer	0.000505	0.00106	CcSEcCtD
Medroxyprogesterone Acetate—Tinnitus—Methotrexate—esophageal cancer	0.000503	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Tachycardia—Capecitabine—esophageal cancer	0.000503	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Cisplatin—esophageal cancer	0.000502	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Cardiac disorder—Methotrexate—esophageal cancer	0.000501	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Capecitabine—esophageal cancer	0.000501	0.00105	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Capecitabine—esophageal cancer	0.000498	0.00104	CcSEcCtD
Medroxyprogesterone Acetate—Spironolactone—ABCB1—esophageal cancer	0.000492	0.0303	CrCbGaD
Medroxyprogesterone Acetate—Anorexia—Capecitabine—esophageal cancer	0.000491	0.00103	CcSEcCtD
Medroxyprogesterone Acetate—Angiopathy—Methotrexate—esophageal cancer	0.00049	0.00103	CcSEcCtD
Medroxyprogesterone Acetate—Immune system disorder—Methotrexate—esophageal cancer	0.000488	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Mediastinal disorder—Methotrexate—esophageal cancer	0.000487	0.00102	CcSEcCtD
Medroxyprogesterone Acetate—Chills—Methotrexate—esophageal cancer	0.000484	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Capecitabine—esophageal cancer	0.000482	0.00101	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Cisplatin—esophageal cancer	0.000478	0.001	CcSEcCtD
Medroxyprogesterone Acetate—Alopecia—Methotrexate—esophageal cancer	0.000477	0.000999	CcSEcCtD
Medroxyprogesterone Acetate—Mental disorder—Methotrexate—esophageal cancer	0.000473	0.000991	CcSEcCtD
Medroxyprogesterone Acetate—Erythema—Methotrexate—esophageal cancer	0.00047	0.000984	CcSEcCtD
Medroxyprogesterone Acetate—Malnutrition—Methotrexate—esophageal cancer	0.00047	0.000984	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Capecitabine—esophageal cancer	0.000469	0.000983	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Capecitabine—esophageal cancer	0.000466	0.000976	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Capecitabine—esophageal cancer	0.000463	0.000969	CcSEcCtD
Medroxyprogesterone Acetate—Dysgeusia—Methotrexate—esophageal cancer	0.00046	0.000964	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Capecitabine—esophageal cancer	0.000459	0.000962	CcSEcCtD
Medroxyprogesterone Acetate—Back pain—Methotrexate—esophageal cancer	0.000455	0.000952	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Capecitabine—esophageal cancer	0.000454	0.00095	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Capecitabine—esophageal cancer	0.000448	0.000938	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Capecitabine—esophageal cancer	0.000445	0.000932	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Cisplatin—esophageal cancer	0.000444	0.000931	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Capecitabine—esophageal cancer	0.000444	0.00093	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Cisplatin—esophageal cancer	0.000441	0.000923	CcSEcCtD
Medroxyprogesterone Acetate—Constipation—Capecitabine—esophageal cancer	0.000441	0.000923	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Cisplatin—esophageal cancer	0.00044	0.000922	CcSEcCtD
Medroxyprogesterone Acetate—Ill-defined disorder—Methotrexate—esophageal cancer	0.000436	0.000913	CcSEcCtD
Medroxyprogesterone Acetate—Anaemia—Methotrexate—esophageal cancer	0.000434	0.00091	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Capecitabine—esophageal cancer	0.000425	0.000889	CcSEcCtD
Medroxyprogesterone Acetate—Malaise—Methotrexate—esophageal cancer	0.000424	0.000888	CcSEcCtD
Medroxyprogesterone Acetate—Vertigo—Methotrexate—esophageal cancer	0.000422	0.000884	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Capecitabine—esophageal cancer	0.000421	0.000882	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Cisplatin—esophageal cancer	0.000415	0.00087	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Capecitabine—esophageal cancer	0.000409	0.000857	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Capecitabine—esophageal cancer	0.000407	0.000853	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Capecitabine—esophageal cancer	0.000407	0.000853	CcSEcCtD
Medroxyprogesterone Acetate—Convulsion—Methotrexate—esophageal cancer	0.000407	0.000853	CcSEcCtD
Medroxyprogesterone Acetate—Chest pain—Methotrexate—esophageal cancer	0.0004	0.000838	CcSEcCtD
Medroxyprogesterone Acetate—Arthralgia—Methotrexate—esophageal cancer	0.0004	0.000838	CcSEcCtD
Medroxyprogesterone Acetate—Myalgia—Methotrexate—esophageal cancer	0.0004	0.000838	CcSEcCtD
Medroxyprogesterone Acetate—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—esophageal cancer	0.000397	0.000832	CcSEcCtD
Medroxyprogesterone Acetate—Discomfort—Methotrexate—esophageal cancer	0.000395	0.000828	CcSEcCtD
Medroxyprogesterone Acetate—Confusional state—Methotrexate—esophageal cancer	0.000387	0.00081	CcSEcCtD
Medroxyprogesterone Acetate—Anaphylactic shock—Methotrexate—esophageal cancer	0.000384	0.000803	CcSEcCtD
Medroxyprogesterone Acetate—Infection—Methotrexate—esophageal cancer	0.000381	0.000798	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Capecitabine—esophageal cancer	0.00038	0.000795	CcSEcCtD
Medroxyprogesterone Acetate—Nervous system disorder—Methotrexate—esophageal cancer	0.000376	0.000788	CcSEcCtD
Medroxyprogesterone Acetate—Thrombocytopenia—Methotrexate—esophageal cancer	0.000376	0.000787	CcSEcCtD
Medroxyprogesterone Acetate—Skin disorder—Methotrexate—esophageal cancer	0.000373	0.00078	CcSEcCtD
Medroxyprogesterone Acetate—Hyperhidrosis—Methotrexate—esophageal cancer	0.000371	0.000777	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Capecitabine—esophageal cancer	0.00037	0.000774	CcSEcCtD
Medroxyprogesterone Acetate—Anorexia—Methotrexate—esophageal cancer	0.000366	0.000766	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Capecitabine—esophageal cancer	0.000365	0.000763	CcSEcCtD
Medroxyprogesterone Acetate—Hypotension—Methotrexate—esophageal cancer	0.000358	0.000751	CcSEcCtD
Medroxyprogesterone Acetate—Diarrhoea—Capecitabine—esophageal cancer	0.000353	0.000738	CcSEcCtD
Medroxyprogesterone Acetate—Musculoskeletal discomfort—Methotrexate—esophageal cancer	0.000349	0.000732	CcSEcCtD
Medroxyprogesterone Acetate—Insomnia—Methotrexate—esophageal cancer	0.000347	0.000727	CcSEcCtD
Medroxyprogesterone Acetate—Paraesthesia—Methotrexate—esophageal cancer	0.000344	0.000721	CcSEcCtD
Medroxyprogesterone Acetate—Dyspnoea—Methotrexate—esophageal cancer	0.000342	0.000716	CcSEcCtD
Medroxyprogesterone Acetate—Somnolence—Methotrexate—esophageal cancer	0.000341	0.000714	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Capecitabine—esophageal cancer	0.000341	0.000714	CcSEcCtD
Medroxyprogesterone Acetate—Dyspepsia—Methotrexate—esophageal cancer	0.000338	0.000707	CcSEcCtD
Medroxyprogesterone Acetate—Decreased appetite—Methotrexate—esophageal cancer	0.000333	0.000698	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal disorder—Methotrexate—esophageal cancer	0.000331	0.000694	CcSEcCtD
Medroxyprogesterone Acetate—Fatigue—Methotrexate—esophageal cancer	0.000331	0.000693	CcSEcCtD
Medroxyprogesterone Acetate—Vomiting—Capecitabine—esophageal cancer	0.000328	0.000686	CcSEcCtD
Medroxyprogesterone Acetate—Hydrocortisone—ABCB1—esophageal cancer	0.000327	0.0201	CrCbGaD
Medroxyprogesterone Acetate—Rash—Capecitabine—esophageal cancer	0.000325	0.00068	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Capecitabine—esophageal cancer	0.000325	0.00068	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Capecitabine—esophageal cancer	0.000323	0.000676	CcSEcCtD
Medroxyprogesterone Acetate—Feeling abnormal—Methotrexate—esophageal cancer	0.000316	0.000662	CcSEcCtD
Medroxyprogesterone Acetate—Gastrointestinal pain—Methotrexate—esophageal cancer	0.000314	0.000657	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Capecitabine—esophageal cancer	0.000306	0.000641	CcSEcCtD
Medroxyprogesterone Acetate—Urticaria—Methotrexate—esophageal cancer	0.000305	0.000638	CcSEcCtD
Medroxyprogesterone Acetate—Body temperature increased—Methotrexate—esophageal cancer	0.000303	0.000635	CcSEcCtD
Medroxyprogesterone Acetate—Abdominal pain—Methotrexate—esophageal cancer	0.000303	0.000635	CcSEcCtD
Medroxyprogesterone Acetate—Hypersensitivity—Methotrexate—esophageal cancer	0.000283	0.000592	CcSEcCtD
Medroxyprogesterone Acetate—Asthenia—Methotrexate—esophageal cancer	0.000275	0.000576	CcSEcCtD
Medroxyprogesterone Acetate—Pruritus—Methotrexate—esophageal cancer	0.000271	0.000568	CcSEcCtD
Medroxyprogesterone Acetate—Progesterone—ABCB1—esophageal cancer	0.000266	0.0164	CrCbGaD
Medroxyprogesterone Acetate—Diarrhoea—Methotrexate—esophageal cancer	0.000262	0.00055	CcSEcCtD
Medroxyprogesterone Acetate—Dizziness—Methotrexate—esophageal cancer	0.000254	0.000531	CcSEcCtD
Medroxyprogesterone Acetate—Testosterone—ABCB1—esophageal cancer	0.000252	0.0155	CrCbGaD
Medroxyprogesterone Acetate—Vomiting—Methotrexate—esophageal cancer	0.000244	0.000511	CcSEcCtD
Medroxyprogesterone Acetate—Rash—Methotrexate—esophageal cancer	0.000242	0.000507	CcSEcCtD
Medroxyprogesterone Acetate—Dermatitis—Methotrexate—esophageal cancer	0.000242	0.000506	CcSEcCtD
Medroxyprogesterone Acetate—Headache—Methotrexate—esophageal cancer	0.00024	0.000503	CcSEcCtD
Medroxyprogesterone Acetate—Nausea—Methotrexate—esophageal cancer	0.000228	0.000477	CcSEcCtD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC52A3—esophageal cancer	0.000114	0.00029	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—BLVRB—esophageal cancer	0.000114	0.00029	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Biological oxidations—CYP19A1—esophageal cancer	0.000114	0.000289	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling by ERBB4—PIK3CA—esophageal cancer	0.000114	0.000289	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—WIF1—esophageal cancer	0.000113	0.000288	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—ABCB1—esophageal cancer	0.000113	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CTNNA1—esophageal cancer	0.000113	0.000287	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NOTCH2—esophageal cancer	0.000112	0.000286	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metapathway biotransformation—CYP19A1—esophageal cancer	0.000112	0.000285	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CXCL2—esophageal cancer	0.000112	0.000285	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—MYC—esophageal cancer	0.000112	0.000284	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Breast Cancer Pathway—TP53—esophageal cancer	0.000111	0.000281	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—HIF1A—esophageal cancer	0.00011	0.000281	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—EGFR—esophageal cancer	0.000109	0.000277	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PSME2—esophageal cancer	0.000105	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PSME1—esophageal cancer	0.000105	0.000267	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CSNK1A1—esophageal cancer	0.000105	0.000266	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ANXA1—esophageal cancer	0.000104	0.000265	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CRABP1—esophageal cancer	0.000104	0.000265	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—EP300—esophageal cancer	0.000104	0.000265	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NOTCH2—esophageal cancer	0.000104	0.000264	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000103	0.000262	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	0.000102	0.000259	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SST—esophageal cancer	0.000101	0.000258	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—NOTCH1—esophageal cancer	0.000101	0.000258	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NOS2—esophageal cancer	0.0001	0.000255	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TGFBR2—esophageal cancer	9.98e-05	0.000254	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NOTCH1—esophageal cancer	9.94e-05	0.000253	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—GHRL—esophageal cancer	9.89e-05	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOTCH3—esophageal cancer	9.89e-05	0.000252	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PFN1—esophageal cancer	9.79e-05	0.000249	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—FBXW7—esophageal cancer	9.73e-05	0.000248	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—SLC10A2—esophageal cancer	9.69e-05	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CA1—esophageal cancer	9.69e-05	0.000246	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—PIK3CA—esophageal cancer	9.47e-05	0.000241	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PSME2—esophageal cancer	9.46e-05	0.000241	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—PSME1—esophageal cancer	9.46e-05	0.000241	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—SMAD4—esophageal cancer	9.44e-05	0.00024	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Generic Transcription Pathway—MYC—esophageal cancer	9.44e-05	0.00024	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—CREBBP—esophageal cancer	9.33e-05	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PSME2—esophageal cancer	9.32e-05	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—PSME1—esophageal cancer	9.32e-05	0.000237	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC52A3—esophageal cancer	9.27e-05	0.000236	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—BLVRB—esophageal cancer	9.27e-05	0.000236	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—CREBBP—esophageal cancer	9.19e-05	0.000234	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Integrated Pancreatic Cancer Pathway—TP53—esophageal cancer	9.16e-05	0.000233	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CREBBP—esophageal cancer	9.01e-05	0.000229	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NOTCH3—esophageal cancer	8.93e-05	0.000227	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOTCH2—esophageal cancer	8.87e-05	0.000226	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CA2—esophageal cancer	8.86e-05	0.000225	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NOTCH3—esophageal cancer	8.79e-05	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ELMO1—esophageal cancer	8.79e-05	0.000224	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—SMAD4—esophageal cancer	8.73e-05	0.000222	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	8.66e-05	0.00022	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—AKAP13—esophageal cancer	8.59e-05	0.000219	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	8.54e-05	0.000217	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—NOTCH1—esophageal cancer	8.44e-05	0.000215	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS1—esophageal cancer	8.29e-05	0.000211	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PLCE1—esophageal cancer	8.24e-05	0.00021	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ADH7—esophageal cancer	8.24e-05	0.00021	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	8.14e-05	0.000207	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—NOS3—esophageal cancer	8.07e-05	0.000205	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NOTCH2—esophageal cancer	8.01e-05	0.000204	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HIST1H2BM—esophageal cancer	7.93e-05	0.000202	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NOTCH2—esophageal cancer	7.89e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—SLC10A2—esophageal cancer	7.88e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CA1—esophageal cancer	7.88e-05	0.000201	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TGFBR2—esophageal cancer	7.87e-05	0.0002	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PDE4D—esophageal cancer	7.86e-05	0.0002	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—HIF1A—esophageal cancer	7.73e-05	0.000197	CbGpPWpGaD
Medroxyprogesterone Acetate—HSD3B2—Metabolism—PIK3CA—esophageal cancer	7.7e-05	0.000196	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—CREBBP—esophageal cancer	7.66e-05	0.000195	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—CREBBP—esophageal cancer	7.55e-05	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—ERBB2—esophageal cancer	7.55e-05	0.000192	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GNG7—esophageal cancer	7.48e-05	0.00019	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—SMAD4—esophageal cancer	7.45e-05	0.00019	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—KDR—esophageal cancer	7.39e-05	0.000188	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PTGS2—esophageal cancer	7.38e-05	0.000188	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ADH1B—esophageal cancer	7.22e-05	0.000184	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CA2—esophageal cancer	7.21e-05	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Generic Transcription Pathway—MYC—esophageal cancer	7.19e-05	0.000183	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP1B1—esophageal cancer	7.05e-05	0.000179	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—XIAP—esophageal cancer	7e-05	0.000178	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NOTCH1—esophageal cancer	6.96e-05	0.000177	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TYMP—esophageal cancer	6.9e-05	0.000176	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—NOS3—esophageal cancer	6.76e-05	0.000172	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—SMAD4—esophageal cancer	6.72e-05	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP26A1—esophageal cancer	6.71e-05	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PLCE1—esophageal cancer	6.7e-05	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ADH7—esophageal cancer	6.7e-05	0.000171	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CYP19A1—esophageal cancer	6.62e-05	0.000169	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CTNNA1—esophageal cancer	6.62e-05	0.000169	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—SMAD4—esophageal cancer	6.62e-05	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CXCL2—esophageal cancer	6.59e-05	0.000168	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALOX15—esophageal cancer	6.54e-05	0.000166	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—CDKN1A—esophageal cancer	6.45e-05	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—NOTCH1—esophageal cancer	6.43e-05	0.000164	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CREBBP—esophageal cancer	6.31e-05	0.000161	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—TPI1—esophageal cancer	6.24e-05	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTO1—esophageal cancer	6.24e-05	0.000159	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PTGS2—esophageal cancer	6.18e-05	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PSME2—esophageal cancer	6.15e-05	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PSME1—esophageal cancer	6.15e-05	0.000157	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EP300—esophageal cancer	6.14e-05	0.000156	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ANXA1—esophageal cancer	6.12e-05	0.000156	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—BLVRB—esophageal cancer	6.11e-05	0.000156	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC52A3—esophageal cancer	6.11e-05	0.000156	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—HIF1A—esophageal cancer	6.09e-05	0.000155	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALDOB—esophageal cancer	5.98e-05	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SST—esophageal cancer	5.96e-05	0.000152	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ADH1B—esophageal cancer	5.88e-05	0.00015	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—CREBBP—esophageal cancer	5.83e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—KDR—esophageal cancer	5.83e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOTCH3—esophageal cancer	5.8e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—GHRL—esophageal cancer	5.8e-05	0.000148	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GAPDH—esophageal cancer	5.76e-05	0.000147	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—FBXW7—esophageal cancer	5.71e-05	0.000145	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CRABP1—esophageal cancer	5.71e-05	0.000145	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—NOS3—esophageal cancer	5.65e-05	0.000144	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TYMP—esophageal cancer	5.62e-05	0.000143	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Generic Transcription Pathway—MYC—esophageal cancer	5.54e-05	0.000141	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOTCH1—esophageal cancer	5.49e-05	0.00014	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP26A1—esophageal cancer	5.46e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Generic Transcription Pathway—MYC—esophageal cancer	5.46e-05	0.000139	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GNG7—esophageal cancer	5.43e-05	0.000138	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—MYC—esophageal cancer	5.35e-05	0.000136	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALOX15—esophageal cancer	5.32e-05	0.000135	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—ERBB2—esophageal cancer	5.29e-05	0.000134	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—EGFR—esophageal cancer	5.23e-05	0.000133	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOTCH2—esophageal cancer	5.21e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—SLC10A2—esophageal cancer	5.2e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CA1—esophageal cancer	5.2e-05	0.000132	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—EP300—esophageal cancer	5.14e-05	0.000131	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ALDH2—esophageal cancer	5.09e-05	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—TPI1—esophageal cancer	5.08e-05	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTO1—esophageal cancer	5.08e-05	0.000129	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CREBBP—esophageal cancer	4.98e-05	0.000127	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—NOTCH1—esophageal cancer	4.96e-05	0.000126	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—NOTCH1—esophageal cancer	4.88e-05	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALDOB—esophageal cancer	4.87e-05	0.000124	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—GSTT1—esophageal cancer	4.84e-05	0.000123	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP2A6—esophageal cancer	4.78e-05	0.000122	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	4.77e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CA2—esophageal cancer	4.75e-05	0.000121	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GAPDH—esophageal cancer	4.69e-05	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CCND1—esophageal cancer	4.67e-05	0.000119	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CRABP1—esophageal cancer	4.65e-05	0.000118	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TGFBR2—esophageal cancer	4.62e-05	0.000117	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Gene Expression—MYC—esophageal cancer	4.54e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Disease—PIK3CA—esophageal cancer	4.54e-05	0.000116	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS1—esophageal cancer	4.53e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ENO1—esophageal cancer	4.53e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—CDKN1A—esophageal cancer	4.52e-05	0.000115	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—CREBBP—esophageal cancer	4.49e-05	0.000114	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PSME1—esophageal cancer	4.47e-05	0.000114	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PSME2—esophageal cancer	4.47e-05	0.000114	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—NOS3—esophageal cancer	4.46e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—CREBBP—esophageal cancer	4.43e-05	0.000113	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PLCE1—esophageal cancer	4.42e-05	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ADH7—esophageal cancer	4.42e-05	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GNG7—esophageal cancer	4.42e-05	0.000112	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—SMAD4—esophageal cancer	4.37e-05	0.000111	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EP300—esophageal cancer	4.3e-05	0.000109	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—ERBB2—esophageal cancer	4.17e-05	0.000106	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ALDH2—esophageal cancer	4.14e-05	0.000105	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—GSTT1—esophageal cancer	3.94e-05	0.0001	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.9e-05	9.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP2A6—esophageal cancer	3.89e-05	9.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—esophageal cancer	3.88e-05	9.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ADH1B—esophageal cancer	3.88e-05	9.86e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP1B1—esophageal cancer	3.86e-05	9.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Metabolism—PIK3CA—esophageal cancer	3.8e-05	9.67e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—MYC—esophageal cancer	3.75e-05	9.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TYMP—esophageal cancer	3.7e-05	9.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ENO1—esophageal cancer	3.69e-05	9.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS1—esophageal cancer	3.69e-05	9.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CCND1—esophageal cancer	3.68e-05	9.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—EGFR—esophageal cancer	3.66e-05	9.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PSME1—esophageal cancer	3.64e-05	9.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PSME2—esophageal cancer	3.64e-05	9.25e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CYP19A1—esophageal cancer	3.63e-05	9.22e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP26A1—esophageal cancer	3.6e-05	9.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—HIF1A—esophageal cancer	3.58e-05	9.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—CDKN1A—esophageal cancer	3.56e-05	9.07e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALOX15—esophageal cancer	3.51e-05	8.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AR—Gene Expression—MYC—esophageal cancer	3.46e-05	8.81e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—KDR—esophageal cancer	3.42e-05	8.7e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EP300—esophageal cancer	3.39e-05	8.63e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—TPI1—esophageal cancer	3.35e-05	8.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTO1—esophageal cancer	3.35e-05	8.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—HMOX1—esophageal cancer	3.31e-05	8.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	3.25e-05	8.26e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOTCH1—esophageal cancer	3.22e-05	8.2e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALDOB—esophageal cancer	3.21e-05	8.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—PIK3CA—esophageal cancer	3.18e-05	8.09e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—esophageal cancer	3.18e-05	8.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—ABCB1—esophageal cancer	3.18e-05	8.08e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP1B1—esophageal cancer	3.14e-05	7.98e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GAPDH—esophageal cancer	3.09e-05	7.87e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—AKR1C3—Signaling Pathways—TP53—esophageal cancer	3.08e-05	7.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CRABP1—esophageal cancer	3.06e-05	7.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—MYC—esophageal cancer	2.95e-05	7.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CYP19A1—esophageal cancer	2.95e-05	7.51e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CREBBP—esophageal cancer	2.92e-05	7.43e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GNG7—esophageal cancer	2.91e-05	7.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—EGFR—esophageal cancer	2.89e-05	7.35e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ALDH2—esophageal cancer	2.73e-05	6.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—HMOX1—esophageal cancer	2.69e-05	6.85e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Gene Expression—MYC—esophageal cancer	2.67e-05	6.79e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—EP300—esophageal cancer	2.64e-05	6.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—NR3C1—Gene Expression—MYC—esophageal cancer	2.63e-05	6.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—NOS3—esophageal cancer	2.62e-05	6.66e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—GSTT1—esophageal cancer	2.6e-05	6.61e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—ABCB1—esophageal cancer	2.58e-05	6.57e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP2A6—esophageal cancer	2.57e-05	6.53e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—PIK3CA—esophageal cancer	2.51e-05	6.38e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—ERBB2—esophageal cancer	2.45e-05	6.23e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ENO1—esophageal cancer	2.43e-05	6.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS1—esophageal cancer	2.43e-05	6.19e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—PGR—Signaling Pathways—TP53—esophageal cancer	2.43e-05	6.17e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	2.4e-05	6.11e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PSME1—esophageal cancer	2.4e-05	6.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PSME2—esophageal cancer	2.4e-05	6.1e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CCND1—esophageal cancer	2.16e-05	5.5e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—CREBBP—esophageal cancer	2.12e-05	5.4e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—CDKN1A—esophageal cancer	2.09e-05	5.32e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP1B1—esophageal cancer	2.07e-05	5.27e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EP300—esophageal cancer	1.99e-05	5.06e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—esophageal cancer	1.95e-05	4.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CYP19A1—esophageal cancer	1.95e-05	4.95e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—NOS3—esophageal cancer	1.9e-05	4.83e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—HMOX1—esophageal cancer	1.78e-05	4.52e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PTGS2—esophageal cancer	1.74e-05	4.42e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—MYC—esophageal cancer	1.73e-05	4.41e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—CREBBP—esophageal cancer	1.73e-05	4.39e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—ABCB1—esophageal cancer	1.7e-05	4.34e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—EGFR—esophageal cancer	1.7e-05	4.31e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—NOS3—esophageal cancer	1.55e-05	3.93e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—PIK3CA—esophageal cancer	1.47e-05	3.74e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—EP300—esophageal cancer	1.45e-05	3.68e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—ESR1—Signaling Pathways—TP53—esophageal cancer	1.42e-05	3.62e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PTGS2—esophageal cancer	1.41e-05	3.6e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—EP300—esophageal cancer	1.18e-05	2.99e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—CREBBP—esophageal cancer	1.14e-05	2.9e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C8—Metabolism—PIK3CA—esophageal cancer	1.07e-05	2.72e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—NOS3—esophageal cancer	1.02e-05	2.59e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PTGS2—esophageal cancer	9.33e-06	2.37e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP2C9—Metabolism—PIK3CA—esophageal cancer	8.7e-06	2.21e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—EP300—esophageal cancer	7.76e-06	1.97e-05	CbGpPWpGaD
Medroxyprogesterone Acetate—CYP3A4—Metabolism—PIK3CA—esophageal cancer	5.74e-06	1.46e-05	CbGpPWpGaD
